Kai Fa Chen, Age 6714515 Viva Dr, Corona, CA 92880

2012030, Nov 29, 2012

May 22, 2012

13/477095

Anna Katrin Szardenings - Torrance CA, US
Hartmuth C. Kolb - Playa Del Rey CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Gang Chen - Rancho Paios Verdes CA, US
Umesh B. Gangadharmath - Los Angeles CA, US
Dhanalakshmi Kasi - Los Angeles CA, US
Changhui Liu - Los Angeles CA, US
Anjana Sinha - San Diego CA, US
Eric Wang - San Diego CA, US
Chul Yu - Los Angeles CA, US
Wei Zhang - Los Angeles CA, US
Kai Chen - San Gabriel CA, US
Vani P. Mocharla - Los Angeles CA, US
Peter J.H. Scott - Ypsilanti MI, US

SIEMENS MEDICAL SOLUTIONS USA, INC. - Malvern PA

C07D 471/04
C07D 471/14

546 82, 546 85, 546 86, 546 87

Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

2013032, Dec 5, 2013

Jun 4, 2013

13/909684

Kai Chen - San Gabriel CA, US
Koon Y. Pak - Malvern PA, US

A61K 51/04
G01N 33/50
A61B 6/03
A61K 51/08
A61M 5/00
A61B 5/00

424 189, 600431, 600427, 546 12, 530330, 435 29

Embodiments provide dual modality probes for imaging phosphatidylserine (PS) exposure and other anionic membrane surfaces. In various embodiments, the probes were constructed by utilizing a) the high selectivity of synthetic zinc (II) dipicolylamine coordination complexes (Zn-DPA) for targeting externalized PS which over-expresses in apoptotic and necrotic cells, b) a near-infrared (NIR) dye for optical imaging, and c) a widely used clinically approved radionuclide for PET (or SPECT) imaging. A variety of linking elements were incorporated into the probes between the Zn-DPA and radionuclide motif to modulate the pharmacokinetics. The in vitro and in vivo data of radiolabeled dipicolylamine probes demonstrated their utilities for imaging PS exposure with multiple imaging modalities.

2022031, Oct 6, 2022

Jun 23, 2022

17/847899

Michael Cieslak - Los Angeles CA, US
Jiayao Yu - Venice CA, US
Kai Chen - Manhattan Beach CA, US
Farnaz Azmoodeh - Venice CA, US
Michael David Marr - Monroe WA, US
Jun Huang - Beverly Hills CA, US
Zahra Ferdowsi - Marina del Rey CA, US

G06F 1/20
G01K 3/00
G06F 9/445

The systems and methods manage thermal states of a device through user configuration of a client application on the device. The systems and methods set thermal thresholds associated with the device. The systems and methods infer the thermal thresholds from information gathered by a client application running on the device. The systems and methods implement a stored policy associated with a violation of one of the thermal thresholds by one of the monitored thermal states.

2022027, Sep 1, 2022

May 18, 2022

17/747812

Michael Cieslak - Los Angeles CA, US
Jiayao Yu - Venice CA, US
Kai Chen - Manhattan Beach CA, US
Farnaz Azmoodeh - Venice CA, US
Michael David Marr - Monroe WA, US
Jun Huang - Beverly Hills CA, US
Zahra Ferdowsi - Marina del Rey CA, US
Olamide Valerie Olatunji - Los Angeles CA, US
David Boyle - Santa Monica CA, US
Claire Reinert - Seattle WA, US

G06F 11/34
G06F 11/14

Systems, devices, media, and methods are presented for releasing an application feature in incremental stages while monitoring the application for anomalies. The feature includes a package of code and an action setting. The methods in some implementations include identifying active devices on which the application has been installed, monitoring the application according to a set of metrics, activating the feature by changing its action setting for a first segment of the active devices, pausing the feature if an anomaly is detected among the set of metrics, and generating a repair ticket. As long as no anomaly is detected, the activating step proceeds for subsequent segments of the active devices, iteratively, until the release is completed. A feature rank may be used to process and release a plurality of features in order of priority.

2020020, Jul 2, 2020

Mar 7, 2017

16/303913

- Los Angeles CA, US
Boris A Kashemirov - Los Angeles CA, US
Kai Chen - San Gabriel CA, US

A61K 51/04

A novel method for rapidly and efficiently introducing fluorine into the P-C-P backbone of bisphosphonates starting from readily accessible diazomethylenebisphosphonate esters is provided. The method is applied successfully to create novel [F]-labeled bisphosphonates for positron emission tomography imaging. Some versions of the method include reacting a diazomethylenebisphosphonate tetraalkyl ester with a fluorinating agent in the presence of an acidic HF/base complex and a t-butyl hypohalite to produce a halofluoromethylenebisphosphonate tetraalkyl ester, and dealkylating the halofluoromethylenebisphosphonate alkyl ester to produce a halofluoromethylenebis(phosphonic acid). Methods of replacing the halogen group with hydrogen are further provided. F-labeled bisphosphonates prepared by the methods, and methods of using such compounds for positron emission tomography imaging in patients and animal models, are also provided.

2018037, Dec 27, 2018

Sep 5, 2018

16/122545

- Pasadena CA, US
Russell D. Lewis - Pasadena CA, US
Kai Chen - Pasadena CA, US
Frances H. Arnold - Pasadena CA, US

California Institute of Technology - Pasadena CA

C12N 9/02
C07F 7/08

The present invention provides compositions and methods for catalyzing the formation of carbon-silicon bonds using heme proteins. In certain aspects, the present invention provides heme proteins, including variants and fragments thereof, that are capable of carrying out in vitro and in vivo carbene insertion reactions for the formation of carbon-silicon bonds. In other aspects, the present invention provides methods for producing an organosilicon product, the method comprising providing a silicon-containing reagent, a carbene precursor, and a heme protein; and combining the components under conditions sufficient to produce an organosilicon product. Host cells expressing the heme proteins are also provided by the present invention.

2018027, Sep 27, 2018

Mar 7, 2018

15/914788

- Pasadena CA, US
Xiongyi Huang - Pasadena CA, US
Kai Chen - Pasadena CA, US

California Institute of Technology - Pasadena CA

C12N 9/02
C12P 17/10
C12P 17/12

Provided herein are methods for producing an organoboron product. The methods include combining a boron-containing reagent and a carbene precursor in the presence of a heme protein, e.g., a cytochrome c, a cytochrome P450, a globin, a protoglobin, a nitric oxide dioxygenase, a peroxidase, or a catalase, or a variant thereof, under conditions sufficient to form the organoboron product. Reaction mixtures for producing organoboron products are also described, as well as whole-cell catalysts comprising heme proteins and variants thereof for forming carbon-boron bonds.

2017021, Aug 3, 2017

Feb 1, 2017

15/422360

- Pasadena CA, US
Russell D. Lewis - Pasadena CA, US
Kai Chen - Pasadena CA, US
Frances H. Arnold - Pasadena CA, US

California Institute of Technology - Pasadena CA

C12N 9/02
C07F 7/08

The present invention provides compositions and methods for catalyzing the formation of carbon-silicon bonds using heme proteins. In certain aspects, the present invention provides heme proteins, including variants and fragments thereof, that are capable of carrying out in vitro and in vivo carbene insertion reactions for the formation of carbon-silicon bonds. In other aspects, the present invention provides methods for producing an organosilicon product, the method comprising providing a silicon-containing reagent, a carbene precursor, and a heme protein; and combining the components under conditions sufficient to produce an organosilicon product. Host cells expressing the heme proteins are also provided by the present invention.